Predictors of pilosebaceous unit responsiveness to testosterone therapy in patients with hypogonadotrophic hypogonadism

Andrologia

Volumn 43, Issue 6, 2011, Pages 422-427

  Dhiman, P ^a   Bhansali, A ^a   Prasad, R ^a   Dutta, P ^a   Walia, R ^a   Ravikiran, M ^a  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

CAG repeats; Hypogonadotrophic hypogonadism; Pilosebaceous unit; Testosterone therapy

Indexed keywords

ANDROGEN RECEPTOR; ESTRADIOL; FOLLITROPIN; LUTEINIZING HORMONE; NANDROLONE DECANOATE; TESTOSTERONE; TESTOSTERONE ISOCAPROATE; TESTOSTERONE PHENYLPROPIONATE; TESTOSTERONE PROPIONATE; UNCLASSIFIED DRUG;

ADULT; ANDROGEN THERAPY; ARTICLE; CAG REPEAT; CLINICAL ARTICLE; DNA SEQUENCE; EXON; GENOMICS; HAIR; HORMONE ACTION; HUMAN; HYPOGONADOTROPIC HYPOGONADISM; MALE; TREATMENT RESPONSE; VIRILIZATION;

ADULT; BASE SEQUENCE; DNA PRIMERS; ESTRADIOL; EXONS; FOLLICLE STIMULATING HORMONE; HORMONE REPLACEMENT THERAPY; HUMANS; KALLMANN SYNDROME; LUTEINIZING HORMONE; MALE; POLYMERASE CHAIN REACTION; RECEPTORS, ANDROGEN; TESTOSTERONE; TRINUCLEOTIDE REPEATS;

EID: 80054949864     PISSN: 03034569     EISSN: 14390272     Source Type: Journal    
DOI: 10.1111/j.1439-0272.2010.01093.x     Document Type: Article

References (23)

1. Albuisson J, Pecheux C, Carel JC (2004) Kallmann syndrome: 14 novel mutations in KAL1 and FGFR1 (KAL2). Hum Mutat 25:98-99.
2. Bardin CW, Ross GT, Rifkind AB, Cargille CM, Lipsett MB (1969) Studies of the pituitary-Leydig cell axis in young men with hypogonadotropic hypogonadism and hyposmia: comparison with normal men, prepubertal boys, and hypopituitary patients. J Clin Invest 48:2046-2051.
3. Bhagavath B, Ozata M, Ozdemir IC (2005) The prevalence of gonadotropin-releasing hormone receptor mutations in a large cohort of patients with hypogonadotropic hypogonadism. Fertil Steril 84:951-957.
4. Bick D, Franco B, Sherins RJ (1992) Brief report: intragenic deletion of the KALIG-1 gene in Kallmann's syndrome. N Engl J Med 326:1752-1755.
5. Block GJ, Boer H, Gooren LJ, Van der Veen EA (1997) Growth hormone substitution in adult growth hormone deficient men augments androgen effects on the skin. Clin Endocrinol 47:29-36.
6. Chen W, Tsai S-J, Sheu H-M, Tsai J-C, Zouboulis CC (2010) Testosterone synthesized in cultured human SZ95 sebocytes mainly derives from dehydroepiandrosterone. Exp Dermatol 19:470-472.
7. Choong CS, Wilson EM (1998) Trinucleotide repeats in the human androgen receptor: a molecular basis for diseases. J Mol Endocrinol 21:235-257.
8. Daly AK, Fairbrother KS, Andreassen OA, London SJ, Idle JR, Steen VM (1996) Characterization and PCR-based detection of two different hybrid CYP2D7P/CYP2D6 alleles associated with the poor metabolizer phenotype. Pharmacogenetics 6:319-328.
9. Dode C, Levilliers J, Dupont JM (2003) Loss-of-function mutations in FGFR1 cause autosomal dominant Kallmann syndrome. Nat Genet 33:463-465.
10. Hardy DO, Scher HI, Bogenreider T, Sabbatini P, Zhang ZF, Nanus DM, Catterall JF (1996) Androgen receptor CAG repeat lengths in prostate cancer: correlation with age of onset. J Clin Endocrinol Metab 8:4400-4405.
11. Irvine RA, Ross RK, Stallcup MR, Coetzee GA (2001) Inhibition of p160-mediated coactivation with increasing androgen receptor polyglutamine length. Hum Mol Genet 9:267-274.
12. Mifsud A, Sim CKS, Boettger-Tong H, Moreira S, Lamb DJ, Lipshultz LI, Yong EL (2001) Trinucleotide (CAG) repeat polymorphisms in the androgen receptor gene: molecular markers of the risk for male infertility. Fertil Steril 75:275-281.
13. Pathomvanich D, Pongratananukul S, Thienthaworn P (2002) A random study of Asian male androgenetic alopecia in Bangkok, Thailand. Dermatol Surg 28:804-807.
14. Pitteloud N, Acierno JS, Meysing A (2006) Mutations in fibroblast growth factor receptor 1 cause both Kallmann syndrome and normosmic idiopathic hypogonadotropic hypogonadism. Proc Natl Acad Sci USA 103:6281-6286.
15. Raivio J, Falardeau J, Dwyer A, Quinton R, Hayes FJ, Huges VA (2007) Reversal of idiopathic hypogonadotropic hypogonadism. N Engl J Med 357:863-873.
16. Rugarli EI (1999) Kallmann Syndrome and the link between olfactory and reproductive development. Am J Hum Genet 65:943-948.
17. Samson M, Labrie F, Zouboulis CC, Luu-The V (2009) Bio-synthesis of dihydrotestosterone by a pathway that does not require testosterone as intermediate in the SZ95 sebaceousgland cell line. J Invest Dermatol 2010; 130:602-604.
18. Sato N, Katsumata N, Kagami M (2004) Clinical assessment and mutation analysis of Kallmann syndrome 1 (KAL1) and fibroblast growth factor receptor 1 (FGFR1, or KAL2) in five families and 18 sporadic patients. J Clin Endocrinol Metab 89:1079-1088.
19. Sharpe RM, Fraser HM, Brougham MFH, McKinnell C, Morris KD, Kelnar CJH (2003) Role of the neonatal period of pituitary-testicular activity in germ cell proliferation and differentiation in the primate testis. Hum Reprod 18:2110-2117.
20. Tut TG, Ghadessy FJ, Trifiro MA, Pinsky L, Yong EL (1997) Long polyglutamine tracts in the androgen receptor are associated with reduced trans-activation, impaired sperm production, and male infertility. J Clin Endocrinol Metab 82:3777-3783.
21. Zhou ZX, Wong CI, Sar M (1994) The androgen receptor: an overview. Recent Prog Horm Res 99:249-274.
22. Zitzmann M, Nieschlag E (2003) The CAG repeat polymorphism within the androgen receptor gene and maleness. Int J Androl 26:76-83.
23. Zitzmann M, Nieschlag E (2007) Androgen receptor gene CAG repeat length and body mass index modulate the safety of long term intramuscular testosterone undecanoate therapy in hypogonadal men. J Clin Endocrinol Metab 92:3844-3853.